

07<sup>th</sup> February, 2025

To,

<b>The Corporate Relationship Department</b> <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <b>Scrip Code: 539523</b>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. <b>Scrip Symbol: ALKEM</b>
---	--

**Sub: Outcome of Board Meeting held on 07<sup>th</sup> February, 2025**

Dear Sir(s)/ Madam,

This is with reference to our earlier intimation dated 28<sup>th</sup> January, 2025, pursuant to Regulation 30 read with Regulation 33, Regulation 42 and Regulation 43 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), the Board of Directors of the Company, at its meeting held today i.e. 07<sup>th</sup> February, 2025 have *inter alia*:

- a. Approved the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31<sup>st</sup> December, 2024.

A copy of the said Financial Results and Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the SEBI LODR Regulations, is enclosed herewith.

- b. Declared an Interim Dividend of Rs. 37/- (Rupees Thirty-Seven only) per equity share on the face value of Rs. 2/- per share for financial year 2024-2025 pursuant to Regulation 43 read with Regulation 30 of SEBI LODR Regulations.

The date of payment of Interim Dividend shall be on and from 28<sup>th</sup> February, 2025.

Further, as informed vide our letter dated 28<sup>th</sup> January, 2025, submitted to the Stock Exchanges pursuant to Regulation 42 of SEBI LODR Regulations, the record date for the purpose of payment of Interim Dividend for financial year 2024-2025 would be Friday, 14<sup>th</sup> February, 2025.

The meeting of the Board of Directors of the Company commenced at 11.00 a.m. and concluded at 01.40 p.m.

Kindly take the same on record.

Sincerely,  
For **Alkem Laboratories Limited**

  
**Manish Narang**  
**President - Legal, Company Secretary & Compliance Officer**

Encl.: a/a

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF Alkem Laboratories Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Alkem Laboratories Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and nine months ended December 31, 2024 ("the Statement") which includes one branch of the Group located at Nepal being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure 1 to this report.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

9 1

# Deloitte Haskins & Sells LLP

6. We did not review the interim financial information / financial results of five subsidiaries included in the consolidated unaudited financial results, whose interim financial information/ financial results reflect total revenues of Rs.4,141.0 million and Rs.12,111.7 million for the quarter and nine months ended December 31, 2024 respectively, total net profit after tax of Rs.308.4 million and Rs.1,054.1 million for the quarter and nine months ended December 31, 2024 respectively and total comprehensive income (net) of Rs.230.8 million and Rs.1,021.2 million for the quarter and nine months ended December 31, 2024 respectively, as considered in the Statement. These interim financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

7. The consolidated unaudited financial results includes the interim financial information/ financial results of nineteen subsidiaries which have not been reviewed by their auditors, whose financial information/ financial results reflect total revenue of Rs.1,817.5 million and Rs.5,420.7 million for the quarter and nine months ended December 31, 2024 respectively, total net (loss)/profit after tax of Rs.(85.3) million and Rs.39.4 million for the quarter and nine months ended December 31, 2024 respectively and Total comprehensive (loss)/income of Rs.(187.7) million and Rs.34.0 million for the quarter and nine months ended December 31, 2024 respectively, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information / financial results are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information / results certified by the Management.

8. The comparative financial information of the Group for the quarter and nine months ended December 31, 2023 and for the year ended March 31, 2024 prepared in accordance with Ind AS included in this Statement have been reviewed/audited, as applicable, by the predecessor auditor. The reports of the predecessor auditor on this comparative financial information dated February 09, 2024 and May 29, 2024 respectively expressed an unmodified conclusion/unmodified opinion, as applicable.

Our conclusion on the Statement is not modified in respect of this matter.

For **Deloitte Haskins & Sells LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)

**Rupen K. Bhatt**  
(Partner)  
(Membership No. 046930)  
(UDIN: 250469308MOD&I2649)

4

Place: Mumbai  
Date: February 07, 2025

# Deloitte Haskins & Sells LLP

## ANNEXURE I TO THE INDEPENDENT AUDITOR'S REVIEW REPORT

(Referred to in paragraph 4 under Independent Auditor's Review Report of even date)

S.N.	Name of the component	Relationship
1	Alkem Laboratories Limited	Parent
2	S&B Holdings S.a.r.l,	Wholly Owned Subsidiary
3	The Pharma Network LLC, USA (TPN)	Wholly Owned Subsidiary of S&B Holdings S.a.r.l.
4	Ascend Laboratories LLC, USA	Wholly Owned Subsidiary of TPN
5	S & B Pharma LLC	Wholly Owned Subsidiary of TPN
6	Pharmacor Pty Limited, Australia	Wholly Owned Subsidiary
7	Pharmacor SPA, Chile (incorporated on 22-11-2024)	Wholly Owned Subsidiary of Pharmacor Pty Limited, Australia
8	Enzene Biosciences Ltd, India	Subsidiary
9	Ascend Laboratories (PTY) Ltd, South Africa	Wholly Owned Subsidiary
10	Cachet Pharmaceuticals Private Limited, India	Subsidiary
11	Indchemie Health Specialties Private Limited, India	Subsidiary
12	Alkem Laboratories Corporation, Philippines	Wholly Owned Subsidiary
13	Ascend GmbH, Germany	Wholly Owned Subsidiary
14	Ascend Laboratories SDN BHD., Malaysia	Wholly Owned Subsidiary
15	Ascend Laboratories SpA Chile (Ascend Chile)	Wholly Owned Subsidiary
16	Pharma Network SpA, Chile	Wholly Owned Subsidiary of Ascend Chile
17	Ascend Laboratories S.A. DE C.V., Mexico	Wholly Owned Subsidiary of Ascend Chile
18	Alkem Laboratories Korea Inc, Korea	Wholly Owned Subsidiary
19	Pharmacor Ltd, Kenya	Wholly Owned Subsidiary
20	The Pharma Network LLP, Kazakhstan	Wholly Owned Subsidiary
21	Ascend Laboratories (UK) Ltd, UK	Wholly Owned Subsidiary
22	Ascend Laboratories Ltd, Canada	Wholly Owned Subsidiary
23	Alkem Foundation, India	Wholly Owned Subsidiary
24	Connect 2 Clinic Private Limited, India	Wholly Owned Subsidiary
25	Ascend Laboratories SAS, Colombia	Wholly Owned Subsidiary
26	Pharmacor Limited, New Zealand	Wholly Owned Subsidiary
27	Enzene Inc., USA	Wholly Owned Subsidiary of Enzene Biosciences Ltd, India
28	Alkem Medtech Private Limited, India	Wholly Owned Subsidiary
29	Alixer Nexgen Therapeutics Limited (Incorporated on July 12, 2024)	Wholly Owned Subsidiary
30	Alkem Wellness Limited (incorporated on September 16, 2024)	Wholly Owned Subsidiary

A. h.



# ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

## Statement of Unaudited Consolidated Financial Results for the Quarter and Nine months ended 31 December 2024

(₹ in Million except per share data)


Particulars	Quarter ended			Nine months ended		Year ended
	31.12.2024 (Unaudited)	30.09.2024 (Unaudited)	31.12.2023 (Unaudited)	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)
<b>1 Income</b>						
(a) Revenue from Operations	33,742.8	34,146.7	33,238.7	98,207.7	97,317.6	126,675.8
(b) Other Income	929.9	1,344.8	936.4	3,477.8	2,226.7	3,108.4
<b>Total Income</b>	<b>34,672.7</b>	<b>35,491.5</b>	<b>34,175.1</b>	<b>101,685.5</b>	<b>99,544.3</b>	<b>129,784.2</b>
<b>2 Expenses</b>						
(a) Cost of materials consumed	9,240.1	9,021.7	8,385.4	26,633.4	24,958.3	32,945.9
(b) Purchases of stock-in-trade	3,974.8	3,539.2	4,608.1	11,340.6	12,481.7	16,288.7
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,171.6)	(513.9)	51.9	(3,124.2)	861.8	141.2
(d) Employee benefits expense	6,248.1	6,104.9	5,721.5	18,375.7	16,951.8	22,010.1
(e) Finance costs	360.3	281.4	254.6	932.8	855.5	1,124.1
(f) Depreciation and amortisation expense	852.8	789.1	695.6	2,446.7	2,158.7	2,993.0
(g) Other expenses	7,857.5	8,466.5	7,395.9	23,773.6	23,628.9	32,835.0
<b>Total Expenses</b>	<b>27,362.0</b>	<b>27,688.9</b>	<b>27,113.0</b>	<b>80,378.6</b>	<b>81,896.7</b>	<b>108,338.0</b>
<b>3 Profit before exceptional items and tax (1) - (2)</b>	<b>7,310.7</b>	<b>7,802.6</b>	<b>7,062.1</b>	<b>21,306.9</b>	<b>17,647.6</b>	<b>21,446.2</b>
<b>4 Exceptional items (refer note 5)</b>	-	-	(513.1)	-	(1,089.7)	(1,214.9)
<b>5 Profit before tax (3) + (4)</b>	<b>7,310.7</b>	<b>7,802.6</b>	<b>6,549.0</b>	<b>21,306.9</b>	<b>16,557.9</b>	<b>20,231.3</b>
<b>6 Tax expense / (credit)</b>						
(a) Current tax	1,590.4	1,558.8	1,136.0	4,393.5	3,384.3	4,222.8
(b) Deferred tax	(687.6)	(775.8)	(629.8)	(2,016.5)	(1,896.2)	(2,106.1)
<b>Total Tax Expense (a + b)</b>	<b>902.8</b>	<b>783.0</b>	<b>506.2</b>	<b>2,377.0</b>	<b>1,488.1</b>	<b>2,116.7</b>
<b>7 Profit for the period (5) - (6)</b>	<b>6,407.9</b>	<b>7,019.6</b>	<b>6,042.8</b>	<b>18,929.9</b>	<b>15,069.8</b>	<b>18,114.6</b>
<b>8 Other Comprehensive Income (net of tax)</b>						
(a) (i) Items that will not be reclassified to profit or loss	(37.6)	(66.4)	(26.4)	(153.8)	(95.7)	(93.4)
(ii) Income tax relating to items that will not be reclassified to profit or loss	13.0	21.4	8.2	50.4	31.9	29.8
(b) (i) Items that will be reclassified to profit or loss	145.6	106.0	73.0	326.5	340.7	264.0
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
<b>Total Other Comprehensive Income (net of tax)</b>	<b>121.0</b>	<b>61.0</b>	<b>54.8</b>	<b>223.1</b>	<b>276.9</b>	<b>200.4</b>
<b>9 Total Comprehensive Income for the period (7) + (8)</b>	<b>6,528.9</b>	<b>7,080.6</b>	<b>6,097.6</b>	<b>19,153.0</b>	<b>15,346.7</b>	<b>18,315.0</b>
<b>10 Profit attributable to</b>						
a) Owners of the Company	6,258.2	6,886.4	5,949.6	18,596.2	15,022.1	17,957.7
b) Non-Controlling Interest	149.7	133.2	93.2	333.7	47.7	156.9
<b>11 Other Comprehensive Income attributable to</b>						
a) Owners of the Company	120.7	68.5	54.6	233.3	283.3	206.5
b) Non-Controlling Interest	0.3	(7.5)	0.2	(10.2)	(6.4)	(6.1)
<b>12 Total Comprehensive Income attributable to</b>						
a) Owners of the Company	6,378.9	6,954.9	6,004.2	18,829.5	15,305.4	18,164.2
b) Non-Controlling Interest	150.0	125.7	93.4	323.5	41.3	150.8
<b>13 Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>
<b>14 Other Equity</b>						102,881.5
<b>15 Earnings Per Share (not annualised for the periods) (face value of ₹ 2/- each)</b>						
(a) Basic (₹)	52.34	57.60	49.76	155.54	125.64	150.19
(b) Diluted (₹)	52.34	57.60	49.76	155.54	125.64	150.19

**Notes to the Consolidated Financial results:**

- 1 The above unaudited consolidated financial results are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The Consolidated Financial results are prepared in accordance with Ind AS 110 'Consolidated Financial Statements'.
- 2 The above unaudited consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 06 February 2025 and subsequently approved by the Board of Directors at its meeting held on 07 February 2025. The auditors have issued an unmodified review report on the financial results for the quarter and nine months ended 31 December 2024.
- 3 The Board of Directors of the Parent Company at their meeting held on 10 December 2024 have approved the transfer of its Generic Business Undertaking to Alkem Wellness Limited, a wholly owned subsidiary of the Parent Company as a going concern on a slump sale basis. The Parent Company is currently in the process of executing Business Transfer Agreement ("BTA"). Since the carve out of the Generic Business Undertaking is to a wholly owned subsidiary of the Parent Company, there is no impact on the consolidated financial results for the quarter and nine months ended 31 December 2024.
- 4 The comparative financial information of the Group for the quarter and nine months ended 31 December 2023 and for the year ended 31 March 2024, prepared in accordance with Ind AS included in this statement have been reviewed and audited respectively by the predecessor auditor. The reports of the predecessor auditor on these comparative financial information are dated 09 February 2024 and 29 May 2024 respectively.
- 5 Exceptional item for the year ended 31 March 2024 includes impairment loss of ₹ 415.6 Million towards its plant located at Indore. Subsequently, in the previous quarter ended 30 September 2024, the Company as a part of its ongoing initiative of networking strategy and optimization of manufacturing facilities has identified divestment of its Indore facility. Consequently, related assets and liabilities are disclosed as held for sale. These assets and liabilities have been carried at cost as the same are lower than the fair value expected out of sale.  
  
Also, in quarter ended 31 December 2023
  - a) A cyber security incident which compromised business email IDs of certain employees at one of the subsidiaries resulted in a fraudulent transfer of funds of approximately ₹ 513.1 Million which was disclosed as exceptional item for the quarter and nine months ended 31 December 2023. In the subsequent quarter ended 31 March 2024, the Company recovered ₹ 290.4 Million out of the above amount and hence amount of ₹ 222.7 Million was also disclosed under exceptional item for the year ended 31 March 2024.
  - b) The Group had recognised an additional impairment loss of ₹ 576.6 Million in respect of one of the manufacturing units located at St. Louis under S & B Pharma LLC, USA, a step-down subsidiary of the Parent Company, owing to impairment indicators.
- 6 The Board of Directors at its meeting held on 07 February 2025 have declared an interim dividend of ₹ 37 (Rupees only) per equity share (1850% on the face value of ₹ 2 each) for the financials year ending 31 March 2025.
- 7 The Group operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment information has been made.

Place: Mumbai  
Date: 07 February 2025

By Order of the Board  
For Alkem Laboratories Limited

  
B.N. Singh  
Executive Chairman  
DIN: 00760310

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF Alkem Laboratories Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Alkem Laboratories Limited** ("the Company"), which includes a branch located at Nepal for the quarter and nine months ended December 31, 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

g h

# Deloitte Haskins & Sells LLP

5. The comparative financial information of the Company for the quarter and nine months ended December 31, 2023 and for the year ended March 31, 2024 prepared in accordance with Ind AS included in this Statement have been reviewed and audited respectively, by the predecessor auditor. The reports of the predecessor auditor on these comparative financial information dated February 09, 2024 and May 29, 2024 respectively, expressed an unmodified conclusion and unmodified opinion respectively. These previously issued financial information have been adjusted to comply with Ind AS 105 "Non-current Assets Held for Sale and Discontinued Operations" and included in this Statement as comparative financial information. The adjustments made to the previously issued financial information to comply with Ind AS have been reviewed and audited by us, as applicable.

Our conclusion on the Statement is not modified in respect of this matter.

Q h

For **Deloitte Haskins & Sells LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)

**Rupen K. Bhatt**  
(Partner)  
(Membership No. 046930)  
(UDIN: 25046930BMOD8H7608)

Place: Mumbai  
Date: February 07, 2025



**ALKEM LABORATORIES LIMITED**

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

**Statement of Unaudited Standalone Financial Results for the Quarter and Nine months ended 31 December 2024**

(₹ in Million except per share data)

	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2024 (Unaudited)	30.09.2024 (Unaudited)	31.12.2023 (Unaudited)	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)
<b>1</b>	<b>Continuing Operations</b>						
	<b>Income</b>						
	(a) Revenue from Operations	22,868.3	23,547.2	20,088.8	67,685.0	60,955.2	79,638.5
	(b) Other Income	1,691.8	1,201.9	956.6	3,954.7	2,222.0	3,059.9
	<b>Total Income</b>	<b>24,560.1</b>	<b>24,749.1</b>	<b>21,045.4</b>	<b>71,639.7</b>	<b>63,177.2</b>	<b>82,698.4</b>
<b>2</b>	<b>Expenses</b>						
	(a) Cost of materials consumed	6,931.3	6,434.1	5,648.1	19,445.1	17,251.6	22,703.6
	(b) Purchases of stock-in-trade	1,209.0	1,051.1	1,140.2	3,043.7	2,956.1	3,842.7
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(881.5)	(5.2)	41.1	(1,305.3)	(16.4)	(308.5)
	(d) Employee benefits expense	4,184.8	4,087.6	3,850.5	12,293.3	11,511.8	14,780.1
	(e) Finance costs	210.0	171.8	206.6	592.0	598.2	800.7
	(f) Depreciation and amortisation expense	676.1	613.0	568.3	1,919.7	1,713.4	2,391.4
	(g) Other expenses	4,846.4	5,576.7	4,485.5	15,614.1	15,626.6	21,908.8
	<b>Total Expenses</b>	<b>17,176.1</b>	<b>17,929.1</b>	<b>15,940.3</b>	<b>51,602.6</b>	<b>49,641.3</b>	<b>66,118.8</b>
<b>3</b>	<b>Profit before exceptional items and tax from continuing operations (1) - (2)</b>	<b>7,384.0</b>	<b>6,820.0</b>	<b>5,105.1</b>	<b>20,037.1</b>	<b>13,535.9</b>	<b>16,579.6</b>
<b>4</b>	<b>Exceptional items (refer note 5)</b>	-	-	(513.1)	-	(513.1)	(638.3)
<b>5</b>	<b>Profit before tax from continuing operations (3) + (4)</b>	<b>7,384.0</b>	<b>6,820.0</b>	<b>4,592.0</b>	<b>20,037.1</b>	<b>13,022.8</b>	<b>15,941.3</b>
<b>6</b>	<b>Tax expense / (credit)</b>						
	(a) Current tax	1,198.8	1,023.8	641.9	3,133.8	1,895.7	2,330.2
	(b) Deferred tax	(577.1)	(622.3)	(603.1)	(1,735.1)	(1,860.3)	(1,994.0)
	<b>Total Tax expense (a + b)</b>	<b>621.7</b>	<b>401.5</b>	<b>38.8</b>	<b>1,398.7</b>	<b>35.4</b>	<b>336.2</b>
<b>7</b>	<b>Profit for the period after tax from continuing operations (5 - 6)</b>	<b>6,762.3</b>	<b>6,418.5</b>	<b>4,553.2</b>	<b>18,638.4</b>	<b>12,987.4</b>	<b>15,605.1</b>
	<b>Discontinued operations (Refer note 3)</b>						
	Profit before tax from discontinued operations	720.7	856.7	751.8	2,153.7	1,897.4	2,869.0
	Tax expense of discontinued operations	251.8	299.4	262.7	752.6	663.0	1,002.6
<b>8</b>	<b>Profit from discontinued operations (after tax)</b>	<b>468.9</b>	<b>557.3</b>	<b>489.1</b>	<b>1,401.1</b>	<b>1,234.4</b>	<b>1,866.4</b>
<b>9</b>	<b>Profit for the period (7) + (8)</b>	<b>7,231.2</b>	<b>6,975.8</b>	<b>5,042.3</b>	<b>20,039.5</b>	<b>14,221.8</b>	<b>17,471.5</b>
<b>10</b>	<b>Other Comprehensive Income (net of tax)</b>						
	<b>I. In respect of continuing operations:</b>						
	(a) (i) Items that will not be reclassified to profit or loss	(39.9)	(39.9)	(24.1)	(119.5)	(72.3)	(66.8)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	14.0	13.9	8.5	41.8	25.3	23.3
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>II. In respect of discontinuing operations:</b>						
	(a) (i) Items that will not be reclassified to profit or loss*	1.6	1.6	0.0	4.7	0.0	0.0
	(ii) Income tax relating to items that will not be reclassified to profit or loss*	(0.6)	(0.6)	(0.0)	(1.7)	(0.0)	(0.0)
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total Other Comprehensive Income (net of tax)</b>	<b>(24.9)</b>	<b>(25.0)</b>	<b>(15.6)</b>	<b>(74.7)</b>	<b>(47.0)</b>	<b>(43.5)</b>
<b>11</b>	<b>Total Comprehensive Income for the period (9) + (10)</b>	<b>7,206.3</b>	<b>6,950.8</b>	<b>5,026.7</b>	<b>19,964.8</b>	<b>14,174.8</b>	<b>17,428.0</b>
<b>12</b>	<b>Paid-up Equity Share Capital</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>
<b>13</b>	<b>Other Equity</b>						105,307.0
<b>14</b>	<b>Earnings Per Share (not annualised for the periods) (for continuing operations) (face value of ₹ 2/- each)</b>						
	(a) Basic (₹)	56.56	53.68	38.08	155.89	108.63	130.52
	(b) Diluted (₹)	56.56	53.68	38.08	155.89	108.63	130.52
	<b>Earnings Per Share (not annualised for the periods) (for discontinued operations) (face value of ₹ 2/- each)</b>						
	(a) Basic (₹)	3.92	4.66	4.09	11.71	10.32	15.61
	(b) Diluted (₹)	3.92	4.66	4.09	11.71	10.32	15.61
	<b>Earnings Per Share (not annualised for the periods) (from total operations) (face value of ₹ 2/- each)</b>						
	(a) Basic (₹)	60.48	58.34	42.17	167.60	118.95	146.13
	(b) Diluted (₹)	60.48	58.34	42.17	167.60	118.95	146.13

\* Amount less than ₹ 50,000/- is presented as ₹ 0.0 million

**Notes to the Standalone Financial results:**

- 1 The above unaudited standalone financial results are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 2 The above unaudited standalone financial results of the Company were reviewed and recommended by the Audit Committee on 06 February 2025 and subsequently approved by the Board of Directors at its meeting held on 07 February 2025. The auditors have issued an unmodified review report on the financial results for the quarter and nine months ended 31 December 2024.
- 3 The Board of Directors of the Company at their meeting held on 10 December 2024 have approved to transfer its Generic Business Undertaking to Alkem Wellness Limited, a wholly owned subsidiary of the Company as a going concern on a slump sale basis.  
Consequently the proposed transfer of the Generic Business has been disclosed as discontinued operations in accordance with Ind AS 105 "Non-current Assets Held for Sale and Discontinued Operations". The previous period have been restated to give effect to the presentation requirement of Ind AS 105.

The Company is currently in process of executing the Business Transfer Agreement (BTA).


**Key financial information of Discontinued Operations:**

Particulars	Quarter ended			Nine months ended		Year Ended
	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
Total Revenue from Operations	4,880.4	5,172.5	4,857.1	13,784.4	12,868.3	17,838.7
Total expenses	4,159.7	4,315.8	4,105.3	11,630.7	10,970.9	14,969.7
Profit before tax	720.7	856.7	751.8	2,153.7	1,897.4	2,869.0
Total tax expense	251.8	299.4	262.7	752.6	663.0	1,002.6
Net profit for the period/ year	468.9	557.3	489.1	1,401.1	1,234.4	1,866.4

- 4 The comparative financial information of the Company for the quarter and nine months ended 31 December 2023 and for the year ended 31 March 2024, prepared in accordance with Ind AS included in this statement have been reviewed and audited respectively by the predecessor auditor. The reports of the predecessor auditor on these comparative financial information are dated 09 February 2024 and 29 May 2024 respectively. These previously issued financial information have been adjusted to comply with Ind AS 105 " Non-current Assets Held for Sale and Discontinued Operations" and included in this Statement as comparative financial information. The adjustments made to the previously issued financial information to comply with Ind AS have been reviewed and audited by existing auditors, as applicable.
- 5 Exceptional item for the year ended 31 March 2024 includes impairment loss of ₹ 415.6 Million towards its plant located at Indore. Subsequently, in the previous quarter ended 30 September 2024, the Company as a part of its ongoing initiative of networking strategy and optimization of manufacturing facilities has identified divestment of its Indore facility. Consequently, related assets and liabilities are disclosed as held for sale. These assets and liabilities have been carried at cost as the same are lower than the fair value expected out of sale.  
Also, in quarter ended 31 December 2023, a cyber security incident which compromised business email IDs of certain employees at one of the subsidiaries resulted in a fraudulent transfer of funds of approximately ₹ 513.1 Million which was disclosed as exceptional item for the quarter and nine months ended 31 December 2023. In the subsequent quarter ended 31 March 2024, the Company recovered ₹ 290.4 Million out of the above amount and hence amount of ₹ 222.7 Million was disclosed under exceptional item for the year ended 31 March 2024.
- 6 The Board of Directors at its meeting held on 07 February 2025 have declared an interim dividend of ₹ 37 (Rupees only) per equity share (1850% on the face value of ₹ 2 each) for the financials year ending 31 March 2025.
- 7 The Company operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment information has been made.

Place: Mumbai  
Date: 07 February 2025

By Order of the Board  
For Alkem Laboratories Limited

  
B.N. Singh  
Executive Chairman  
DIN: 00760310